Avidity Biosciences Inc

$29.06
(as of Jul 3, 12:53 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Avidity Biosciences Inc

Stock Price
$29.06
Ticker Symbol
RNA
Exchange
NASDAQ

Industry Information for Avidity Biosciences Inc

Sector
Healthcare
Industry
Biotechnology

Company Description for Avidity Biosciences Inc

Website
https://www.aviditybiosciences.com
Country
USA
Full Time Employees
391

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's product candidate Delpacibart etedesiran is for the treatment of myotonic dystrophy type 1 and is currently in phase 3 trial. Its other products in pipeline include Delpacibart zotadirsen for the treatment of duchenne muscular dystrophy, which is under phase 2 clinical development trial; and Delpacibart braxlosiran for the treatment of facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare genetic cardiomyopathies for PRKAG2 syndrome and PLN cardiomyopathy. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Fundamentals for Avidity Biosciences Inc

Market Capitalization
$3,880,744,192
EBITDA
$-376,160,000
Dividends per Share
P/E Ratio
Forward P/E Ratio
0
Earnings per Share
$-2.89
Earnings per Share Estimate Next Year
Profit Margin
Shares Outstanding
120,520,000
Percent Owned by Insiders
5.02%
Percent Owned by Institutions
107.83%
52-Week High
52-Week Low

Technical Indicators for Avidity Biosciences Inc

50-Day Moving Average
200-Day Moving Average
RSI
44.84
ATR
1.7

Analyst Ratings for Avidity Biosciences Inc

Strong Buy
8
Buy
5
Hold
0
Sell
0
Strong Sell
0

News About Avidity Biosciences Inc

Jun 17, 2025, 6:42 AM EST
Wolfe Research initiated coverage on Avidity Biosciences (NASDAQ:RNA) with an outperform rating and a price target of $55.00 on Tuesday. See more.
Jun 14, 2025, 6:53 PM EST
Avidity Biosciences, Inc. See more.
Jun 11, 2025, 8:03 PM EST
Avidity Biosciences, Inc. See more.
Jun 11, 2025, 9:45 AM EST
Investing.com -- Raymond James started coverage on biotechnology companies, rating Avidity Biosciences and Disc Medicine at Strong Buy and assigning Outperform ratings to Dyne Therapeutics, Tectonic Therapeutic, and Wave Life Sciences (NASDAQ:WVE), pointing to a sector-wide opportunity amid “suppressed valuations.” See more.